IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Demyelinating Diseases
Amsterdam UMC, location VUmcmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Demyelinating Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CLEMASTIN University of California, San Francisco | Phase 1/2 | CCC |
Cyclophosphamide Indapta Therapeutics, INC. | Phase 1 | CC |
Idp-023 Indapta Therapeutics, INC. | Phase 1 | CC |
Fludarabine Indapta Therapeutics, INC. | Phase 1 | CC |
Mesna Indapta Therapeutics, INC. | Phase 1 | CC |
Ocrevus Indapta Therapeutics, INC. | Phase 1 | CC |
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →